Walgreens taps SoCore Energy to roll out solar installations in Ohio market
CHICAGO — Walgreens is looking to roll out solar installations at its Ohio-area stores, thanks to a new partnership with a Chicago-based solar developer.
The retailer said that it selected SoCore Energy to provide 90 solar installations for the Ohio-based stores. The partnership began earlier this month with the construction of 20 solar installations at Walgreens stores in Cincinnati. Walgreens and SoCore Energy said that the first 53 solar installations are slated to be completed by Nov. 11.
SoCore said it expects to use Power-One as its exclusive provider of inverters for the projects, while U.S. solar manufacturer SolarWorld will supply high-performance solar panels for the effort.
Walgreens also is marking its 100th solar installation in Mason, Ohio, on Sept. 23, which will include solar demonstrations and feature such guest speakers as White House Council on Environmental Quality chair Nancy Sutley, Walgreens president of community management and store operations Mark Wagner and SoCore Energy president Pete Kadens.
“Walgreens’ impressive sustainability efforts include this substantial commitment to solar power and on-site renewable energy,” Kadens said. “These projects are certainly indicative of Walgreens intent to be one of the most environmentally considerate retailers in the world.”
Walgreens will lease the arrays from SoCore for 10 years.
Mylan, Roche reach deal over cancer drug
PITTSBURGH — Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.
Mylan announced Wednesday that it had entered a settlement and license agreement with Hoffmann La Roche resolving a patent infringement lawsuit over Xeloda (capecitabine) tablets, a drug used to treat breast and colorectal cancers that have spread to other parts of the body.
The litigation was dismissed Tuesday, though additional details of the deal were not disclosed, and it is still subject to review by the Department of Justice and the Federal Trade Commission.
Xeloda had sales of $570 million during the 12-month period ended in June, according to IMS Health.
Pfizer moves forward in Icagen acquisition deal
NEW YORK — The offering period for Pfizer’s acquisition of Icagen has expired, allowing the former to purchase more than 5 million shares in the company, Pfizer said.
Pfizer said that as of Monday, 5.4 million shares of Icagen had been put up for sale. Along with the 1.1 million shares Pfizer already owns, this would give it control of 70.2% of Icagen, which develops drugs for pain and other conditions. Pfizer plans to acquire the remaining shares as well.
Pfizer and Icagen announced in July a deal whereby Pfizer would acquire all the remaining 8.3 million shares of Icagen for $56 million, or $6 per share.